Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 69-76, 2023.
Artigo em Chinês | WPRIM | ID: wpr-953925

RESUMO

ObjectiveTo investigate the effect of Stemona tuberosa alkaloids (STA) on apoptosis and phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and c-Jun N-terminal kinase/p38 mitogen-activated protein kinase (JNK/p38 MAPK) signaling pathways in human lung cancer A549 cells. MethodA549 cells were classified into blank group and STA groups (100, 150, 200, 250, 300 mg⋅L-1). Thiazole blue (MTT) assay and colony formation assay were used to evaluate the proliferation of A549 cells. Apoptosis was observed based on Hoechst 33258 staining, flow cytometry, and Annexin V-FITC/PI staining. Western blot was employed to detect the expression of apoptosis-related proteins cysteine-aspartic acid protease-3 (Caspase-3), B-cell lymphoma-2 (Bcl-2)-associated X protein (Bax), and Bcl-2, and the expression of PI3K, phosphorylated (p)-PI3K, Akt, p-Akt, JNK, p-JNK, p38 MAPK, and p-p38 MAPK. ResultCompared with the blank group, STA groups (150, 200, 250, 300 mg⋅L-1) demonstrated the increase in inhibition rate of cell proliferation (P<0.01) and cell clone inhibition rate, and decrease in cell clone formation rate (P<0.01). In comparison with the blank group, STA groups showed typical characteristics of apoptosis, such as chromatin condensation and enhanced fluorescence reaction. The apoptosis rate of STA groups was significantly higher than that of the blank group (P<0.01). Compared with the blank group, STA (150, 200, 250, 300 mg⋅L-1) significantly up-regulated the protein expression of Caspase-3 and Bax (P<0.05, P<0.01) and down-regulated the expression of Bcl-2 protein (P<0.01). Compared with the blank group, STA had no significant influence on the total protein expression of PI3K, Akt, JNK, and p38 MAPK. However, STA (150, 200, 250, 300 mg⋅L-1) significantly decreased the levels of p-PI3K and p-Akt (P<0.05, P<0.01) and increased the level of p-p38 MAPK (P<0.05, P<0.01). Compared with the blank group, STA (200, 250, 300 mg⋅L-1) significantly raised the level of p-JNK (P<0.05, P<0.01). ConclusionSTA can inhibit the proliferation and induce the apoptosis of A549 cells by inhibiting PI3K/Akt signaling pathway and activating JNK/p38 MAPK signaling pathway.

2.
China Pharmacy ; (12): 1653-1659, 2022.
Artigo em Chinês | WPRIM | ID: wpr-929707

RESUMO

Piperine is a kind of amide alkaloids presenting in Piper nigrum L.,which has the pharmacological action such as protecting cardiovascular system ,regulating glucose and lipid metabolism ,anti-tumor,improving nervous system diseases , anti-inflammation and so on. This paper summarized the pharmacological action and mechanisms of piperine in recent years and found that piperine ,as the main active ingredient of P. nigrum ,could protect the cardiovascular system by reducing inflammation and oxidative stress ;improve mitochondrial function through anti-inflammatory and antioxidant effects ,thereby regulate glucose and lipid metabolism ;play an anti-tumor role by mediating the signaling pathways of Wnt/β-catenin,NF-κB/Nrf-2/KeAP-1/HO-1, PI3K/Akt,TGF-β1/Smad2/ERK1/2;improve neurological diseases by inhibiting autophagy ,relieving inflammation ,improving antioxidant,inhibiting neuronal apoptosis and regulating the expression of related proteins in neurons ;play an anti-inflammatory effect by inhibiting the activity of NF-κB and other signaling pathways and reducing the expression of inflammation-related proteins. However,the mechanism of action of piperine is not perfect ,and most of the studies have been confined to the pharmacological level or a certain signaling pathway and a certain target ,without being able to elucidate the interconnection between the relevant signaling pathway and the specific target from a holistic perspective. In the follow-up ,the specific targets of piperine can be identified and clinical trials can be carried out to provide support for the clinical application of piperine.

3.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 97-104, 2022.
Artigo em Chinês | WPRIM | ID: wpr-940180

RESUMO

ObjectiveTo study the effect of apigenin on the proliferation and apoptosis of human colon cancer CL187 cells and the underlying mechanisms. MethodHuman colorectal cancer CL187 cells were treated with different concentrations of apigenin (0, 30, 45, 60 mg·L-1) according to the results of the preliminary experiment. The proliferation of CL187 cells was detected by methyl thiazolyl tetrazolium (MTT) and colony formation assays, and the apoptosis was observed via Hoechst 33258 staining. Real-time fluorescence quantitative PCR was conducted to determine the mRNA levels of cysteine protease-3 (Caspase-3), B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X protein (Bax) in the CL187 cells treated with apigenin. Western blot was employed to measure the protein levels of Caspase-3, Bcl-2, and Bax associated with apoptosis, protein kinase B (Akt) and phosphorylated Akt (p-Akt) in phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, and extracellular signal-regulated kinases 1/2 (ERK1/2), p-ERK1/2, c-Jun N-terminal kinase (JNK), p-JNK, p38 mitogen-activated protein kinase (MAPK), and p-p38 MAPK protein in MAPK pathway. ResultCompared with the blank group, the apigenin groups had low cell survival rates and high inhibition rates on cell proliferation (P<0.01). Apigenin decreased the cell clone number and clone formation rate, and increased the inhibition rate on clone formation (P<0.01). After CL187 cells were treated with different concentrations of apigenin for 48 h, typical apoptosis characteristics such as nuclear pyknosis, chromatin condensation, and enhanced fluorescence reaction were observed. Compared with blank group, 45, 60 mg·L-1 apigenin treatments down-regulated the mRNA level of anti-apoptotic gene Bcl-2 (P<0.01) and all the apigenin treatments up-regulated those of the pro-apoptotic genes Bax and Caspase-3 (P<0.05, P<0.01). Similarly, apigenin treatments down-regulated the protein level of Bcl-2 (P<0.05, P<0.01) and up-regulated those of Caspase-3 (P<0.05, P<0.01) and Bax (P<0.01, 45, 60 mg·L-1). The blank group had higher protein level of Akt than the 60 mg·L-1 apigenin group (P<0.01), higher protein levels of p-Akt, ERK1/2, and p-ERK1/2 than the 45, 60 mg·L-1 apigenin groups (P<0.01), and higher protein levels of JNK and p-JNK than the apigenin groups (P<0.05, P<0.01). Compared with blank group, 60 mg·L-1 apigenin up-regulated the protein level of p38 MAPK (P<0.05), and all the apigenin groups up-regulated that of p-p38 MAPK (P<0.01). Furthermore, apigenin lowered the p-Akt/Akt ratio (P<0.05, P<0.01) and p-ERK1/2/ERK1/2 ratio (P<0.01), while it increased the p-JNK/JNK ratio (45, 60 mg·L-1; P<0.05, P<0.01) and p-p38 MAPK/p38 MAPK ratio (P<0.05, P<0.01). ConclusionApigenin can inhibit the proliferation and promote the apoptosis of CL187 cells by inhibiting the PI3K/Akt signaling pathway and regulating the expression of proteins in the MAPK signaling pathway.

4.
Chinese Journal of Experimental Traditional Medical Formulae ; (24): 97-104, 2022.
Artigo em Chinês | WPRIM | ID: wpr-940148

RESUMO

ObjectiveTo study the effect of apigenin on the proliferation and apoptosis of human colon cancer CL187 cells and the underlying mechanisms. MethodHuman colorectal cancer CL187 cells were treated with different concentrations of apigenin (0, 30, 45, 60 mg·L-1) according to the results of the preliminary experiment. The proliferation of CL187 cells was detected by methyl thiazolyl tetrazolium (MTT) and colony formation assays, and the apoptosis was observed via Hoechst 33258 staining. Real-time fluorescence quantitative PCR was conducted to determine the mRNA levels of cysteine protease-3 (Caspase-3), B-cell lymphoma-2 (Bcl-2), and Bcl-2-associated X protein (Bax) in the CL187 cells treated with apigenin. Western blot was employed to measure the protein levels of Caspase-3, Bcl-2, and Bax associated with apoptosis, protein kinase B (Akt) and phosphorylated Akt (p-Akt) in phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) pathway, and extracellular signal-regulated kinases 1/2 (ERK1/2), p-ERK1/2, c-Jun N-terminal kinase (JNK), p-JNK, p38 mitogen-activated protein kinase (MAPK), and p-p38 MAPK protein in MAPK pathway. ResultCompared with the blank group, the apigenin groups had low cell survival rates and high inhibition rates on cell proliferation (P<0.01). Apigenin decreased the cell clone number and clone formation rate, and increased the inhibition rate on clone formation (P<0.01). After CL187 cells were treated with different concentrations of apigenin for 48 h, typical apoptosis characteristics such as nuclear pyknosis, chromatin condensation, and enhanced fluorescence reaction were observed. Compared with blank group, 45, 60 mg·L-1 apigenin treatments down-regulated the mRNA level of anti-apoptotic gene Bcl-2 (P<0.01) and all the apigenin treatments up-regulated those of the pro-apoptotic genes Bax and Caspase-3 (P<0.05, P<0.01). Similarly, apigenin treatments down-regulated the protein level of Bcl-2 (P<0.05, P<0.01) and up-regulated those of Caspase-3 (P<0.05, P<0.01) and Bax (P<0.01, 45, 60 mg·L-1). The blank group had higher protein level of Akt than the 60 mg·L-1 apigenin group (P<0.01), higher protein levels of p-Akt, ERK1/2, and p-ERK1/2 than the 45, 60 mg·L-1 apigenin groups (P<0.01), and higher protein levels of JNK and p-JNK than the apigenin groups (P<0.05, P<0.01). Compared with blank group, 60 mg·L-1 apigenin up-regulated the protein level of p38 MAPK (P<0.05), and all the apigenin groups up-regulated that of p-p38 MAPK (P<0.01). Furthermore, apigenin lowered the p-Akt/Akt ratio (P<0.05, P<0.01) and p-ERK1/2/ERK1/2 ratio (P<0.01), while it increased the p-JNK/JNK ratio (45, 60 mg·L-1; P<0.05, P<0.01) and p-p38 MAPK/p38 MAPK ratio (P<0.05, P<0.01). ConclusionApigenin can inhibit the proliferation and promote the apoptosis of CL187 cells by inhibiting the PI3K/Akt signaling pathway and regulating the expression of proteins in the MAPK signaling pathway.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA